CMS Open Payments · Program Year 2024
Creo Medical Inc.
Creo Medical Inc. reported $263,809.12 across General Payments, Research, and Ownership to 276 physicians and teaching hospitals across 276 transactions.
- $263.8K Above-median payer
- All-tracks total
- 276 Above-median volume
- Transactions
- 276 Above-median reach
- Recipients
- +$45.6K
- General Payments vs PY2023
Creo Medical Inc. reported $263,809.12 across all CMS Open Payments tracks (General + Research + Ownership) to 276 physicians and teaching hospitals in Program Year 2024 - ranking #915 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $263,809.12, averaging $955.83 per recipient.
Creo Medical Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
22/100
Total payments
F
12/100
Transaction volume
F
12/100
Physician reach
F
12/100
Payment type diversity
D
50/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer creo-medical-inc Creo Medical Inc.
$263.8K · #915/1,925 · 0.0% industry · PY2024
- TOT $263.8K
- RANK #915
- SHARE 0.0%
- TXN 276
- RCP 276
- CAT 4
- GEN $263.8K
- ΔGEN +$45.6K
- TOP1 17.4%
- PY 2024
Volume peers
Nearest volume peer: Sterilmed, Inc. ($263.8K)
Creo Medical Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Creo Medical Inc.'s CMS-reported General Payments increased by $45.6K (+20.9%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: CREO MEDICAL INC.PY2023: CREO MEDICAL INC.PY2024: Creo Medical Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $218,164.07
- PY2024
- $263,809.12
What the Data Shows for Creo Medical Inc.
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Creo Medical Inc. that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
34 transactions worth $131.2K make "Space Rental or Facility Fees" the top general-payment category in the 4-category breakdown below, 49.7% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Creo Medical Inc. made 4 types of general payments. "Space Rental or Facility Fees" is the largest category at $131.2K, 49.7% of General Payments.
Creo Medical Inc. reports 4 general-payment categories - the top three are Space Rental or Facility Fees (49.7%), Consulting Fee (29.6%), and Travel and Lodging (11.0%). The remaining 1 category make up 9.7% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Creo Medical Inc. divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Space Rental or Facility Fees | $131.2K | 34 | 49.7% |
| Consulting Fee | $78.0K | 28 | 29.6% |
| Travel and Lodging | $29.1K | 69 | 11.0% |
| Food and Beverage | $25.6K | 145 | 9.7% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $138,333.12 (52.4%) of $263,809.12 in this company's General Payments records across 98 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Creo Medical Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Ucsd Medical Center
$45,861.00 across 4 reported transactions
- 2
Mohamed Othman Dr
$31,390.86 across 20 reported transactions
- 3
Norio Fukami Dr
$20,855.27 across 16 reported transactions
- 4
Salmaan Jawaid Dr
$20,225.99 across 23 reported transactions
- 5
The Johns Hopkins Hospital
$20,000.00 across 2 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Creo Medical Inc.'s spend rank (#915 of 1,925, top 48% by spend) and concentration rank (#1,122 of 1,838, bottom 39% least concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- Marinus Pharmaceuticals, Inc. : $279.2K total payments, HHI 807
- 3B Medical, Inc. : $29.3K total payments, HHI 805
- ModernaTX, Inc. : $2.4M total payments, HHI 803
- Community Blood Center : $72.5K total payments, HHI 797
- Acrotech Biopharma Inc. : $317.9K total payments, HHI 793
- KaVo Dental Technologies LLC : $990.42 total payments, HHI 792
- Creo Medical Inc. (this company) : $263.8K total payments, HHI 789
- Progenics Pharmaceuticals, Inc. : $1.7M total payments, HHI 786
- ABB Con-Cise Optical Group LLC : $238.5K total payments, HHI 784
- Vantage Technology LLC : $593.80 total payments, HHI 784
- Vapotherm Inc : $135.8K total payments, HHI 783
- Genzyme Corporation : $57.6M total payments, HHI 783
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Creo Medical Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Creo Medical Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Creo Medical Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
IBSA Pharma Inc.
Evolution Spine, LLC
THD America, Inc.
J. Morita USA, Inc.
Endomagnetics Ltd
Put this to use
Creo Medical Inc. ranks #915 of 1,925 by all-tracks total payments, led by "Space Rental or Facility Fees".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Space Rental or Facility Fees" spend across every manufacturer, not just Creo Medical Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.